Article
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Blood - 15 Nov 2005
Goemans Bianca F, Zwaan Christian M, Harlow Amy, Loonen Anne H, Gibson Brenda E S, Hählen Karel, Reinhardt Dirk, Creutzig Ursula, Heinrich Michael C, Kaspers Gertjan J L
Abstract excerpt
Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.